US 12,247,256 B2
Method of identifying a subject having Kawasaki disease
Jethro Herberg, London (GB); Victoria Wright, London (GB); Michael Levin, London (GB); Clive Hoggart, London (GB); Myrsini Kaforou, London (GB); and Jane Burns, San Diego, CA (US)
Assigned to IMPERIAL COLLEGE INNOVATIONS LIMITED, London (GB); and THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US)
Appl. No. 17/265,579
Filed by Imperial College Innovations Limited, London (GB); and The Regents of the University of California, Oakland, CA (US)
PCT Filed Aug. 5, 2019, PCT No. PCT/EP2019/071052
§ 371(c)(1), (2) Date Feb. 3, 2021,
PCT Pub. No. WO2020/030609, PCT Pub. Date Feb. 13, 2020.
Claims priority of application No. 1812712 (GB), filed on Aug. 4, 2018; and application No. 1814112 (GB), filed on Aug. 30, 2018.
Prior Publication US 2021/0246506 A1, Aug. 12, 2021
Int. Cl. C12Q 1/6837 (2018.01); C12Q 1/686 (2018.01); C12Q 1/6876 (2018.01)
CPC C12Q 1/6876 (2013.01) [C12Q 1/6837 (2013.01); C12Q 1/686 (2013.01)] 12 Claims
OG exemplary drawing
 
1. A method of treating a subject having Kawasaki disease (KD), comprising administering a treatment for KD to the subject, wherein the subject is a child that has been previously identified as having Kawasaki disease by detecting in a subject derived blood RNA sample a modulation in gene expression levels of a gene signature comprising PYROXD2 and at least 4 of the following genes: CACNA1E, DDIAS, KLHL2, SMOX, ZNF185, LINC02035, CLIC3, S100P, IFI27, HS.553068, CD163, and RTN1, wherein the treatment is gamma globulin (IVIg), aspirin, or other anti-inflammatory agents.